These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30782266)

  • 1. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058.
    van de Vijver DAMC; Richter AK; Boucher CAB; Gunsenheimer-Bartmeyer B; Kollan C; Nichols BE; Spinner CD; Wasem J; Schewe K; Neumann A
    Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Cambiano V; Miners A; Dunn D; McCormack S; Ong KJ; Gill ON; Nardone A; Desai M; Field N; Hart G; Delpech V; Cairns G; Rodger A; Phillips AN
    Lancet Infect Dis; 2018 Jan; 18(1):85-94. PubMed ID: 29054789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.
    Juusola JL; Brandeau ML; Owens DK; Bendavid E
    Ann Intern Med; 2012 Apr; 156(8):541-50. PubMed ID: 22508731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study.
    Hu QH; Meyers K; Xu JJ; Chu ZX; Zhang J; Ding HB; Han XX; Jiang YJ; Geng WQ; Shang H
    BMC Infect Dis; 2019 Jul; 19(1):663. PubMed ID: 31345169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016.
    Ong KJ; Desai S; Field N; Desai M; Nardone A; van Hoek AJ; Gill ON
    Euro Surveill; 2017 Oct; 22(42):. PubMed ID: 29067902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.
    Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY
    Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
    Nichols BE; Boucher CAB; van der Valk M; Rijnders BJA; van de Vijver DAMC
    Lancet Infect Dis; 2016 Dec; 16(12):1423-1429. PubMed ID: 27665989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.
    Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M
    J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
    Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
    BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of the daily HIV pre-exposure prophylaxis in men who have sex with men in Barcelona.
    López Seguí F; Oyón Lerga U; Laguna Marmol L; Coll P; Andreu A; Meulbroek M; López Casasnovas G; Estrada Cuxart O; Ara Rey J; Quiñones C; Pérez F; Fernandez J; Rivero À; Ricou Ríos L; Clotet B
    PLoS One; 2023; 18(1):e0277571. PubMed ID: 36649273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
    Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
    J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness.
    Reitsema M; Hoek AJV; van der Loeff MS; Hoornenborg E; van Sighem A; Wallinga J; van Benthem B; Xiridou M
    AIDS; 2020 Mar; 34(4):621-630. PubMed ID: 31895142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation and Operational Research: A Cost-Effective, Clinically Actionable Strategy for Targeting HIV Preexposure Prophylaxis to High-Risk Men Who Have Sex With Men.
    Ross EL; Cinti SK; Hutton DW
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):e61-7. PubMed ID: 26977749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.
    Luz PM; Osher B; Grinsztejn B; Maclean RL; Losina E; Stern ME; Struchiner CJ; Parker RA; Freedberg KA; Mesquita F; Walensky RP; Veloso VG; Paltiel AD
    J Int AIDS Soc; 2018 Mar; 21(3):e25096. PubMed ID: 29603888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and benefits of on-demand HIV preexposure prophylaxis in MSM.
    Durand-Zaleski I; Mutuon P; Charreau I; Tremblay C; Rojas D; Pialoux G; Chidiac C; Capitant C; Spire B; Cotte L; Chas J; Meyer L; Molina JM;
    AIDS; 2018 Jan; 32(1):95-102. PubMed ID: 29210777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan.
    Mizushima D; Nagai Y; Mezzio D; Harada K; Piao Y; Barnieh L; El Moustaid F; Cawson M; Taniguchi T
    J Med Econ; 2023; 26(1):886-893. PubMed ID: 37421417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment.
    Reyes-Urueña J; Campbell C; Diez E; Ortún V; Casabona J
    AIDS Care; 2018 Jun; 30(6):784-792. PubMed ID: 29262694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.